Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
While manual segmentation of lesions and comparisons of PET and SPECT images would take hours to ascertain whole-body tumor burden, an emerging artificial intelligence (AI)-enabled software may provide significantly enhanced diagnostic efficiency.
The updated LesionID Pro software, which will be introduced by GE HealthCare at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, features automated zero-click pre-processing of PET and SPECT images.
Powered by enhanced AI algorithms and designed with input from leading theranostics clinicians, the new LesionID Pro software, which reportedly offers automated analysis of whole-body tumor burden, is slated to be introduced at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference. (Image courtesy of GE HealthCare.)
“(Now) physicians can access critical, patient-specific insights — like tumor volume — without needing to spend hours manually segmenting lesions or aligning multiple scans. This not only helps speed up the diagnostic process but also helps clinicians make fast, informed decisions, which are crucial in cancer care,” noted Jean-Luc Procaccini, the president and CEO of molecular Imaging and computed tomography at GE HealthCare.
Powered by enhanced AI algorithms and designed with input from leading theranostics clinicians, the new LesionID Pro offers automated analysis of whole-body tumor burden, according to GE HealthCare and MIM Software, the developers of LesionID Pro.
Procaccini emphasized that the updated LesionID Pro can play a key role in monitoring the effectiveness of treatments.
“Monitoring treatment response is a critical part of theranostics, and LesionID Pro is designed to significantly streamline the process. By automating the pre-processing of imaging data and providing consistent, quantifiable tumor burden statistics, the software enables clinicians to track changes in tumor volume over time with greater accuracy and less effort,” maintained Procaccini. “This consistency is key for evaluating how well a therapy is working and making timely adjustments to treatment plans. Altogether, it supports precise, data-driven care decisions that can directly impact patient outcomes.”
GE HealthCare noted that LesionID Pro with automated pre-click processing is pending 510(k) clearance by the Food and Drug Administration (FDA).
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.